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Introduction: Fialuridine (FIAU) is a nucleoside analog that is a substrate for bacterial thymidine kinase (TK). Once
phosphorylated by TK, [124I]FIAU becomes trapped within bacteria and can be detected with positron emission
tomography/computed tomography (PET/CT). [124I]FIAU PET/CT has been shown to detect bacteria in patients
withmusculoskeletal bacterial infections. Accurate diagnosis of prosthetic joint infections (PJIs) has proven chal-
lenging because of the lack of a well-validated reference. In the current study, we assessed biodistribution and
dosimetry of [124I]FIAU, and investigated whether [124I]FIAU PET/CT can diagnose PJIs with acceptable accuracy.
Methods: To assess biodistribution and dosimetry, six subjects with suspected hip or knee PJI and six healthy sub-
jects underwent serial PET/CT after being dosed with 74 MBq (2 mCi) [124I]FIAU intravenously (IV). Estimated
radiation doseswere calculatedwith the OLINDA/EXM software. To determine accuracy of [124I]FIAU, 22 subjects
with suspected hip or knee PJI were scanned at 2–6 and 24–30 h post IV injection of 185MBq (5mCi) [124I]FIAU.
Images were interpreted by a single reader blinded to clinical information. Representative cases were reviewed
by 3 additional readers. The utility of [124I]FIAU to detect PJIs was assessed based on the correlation of the
patient's infection status with imaging results as determined by an independent adjudication board (IAB).
Results: The kidney, liver, spleen, and urinary bladder received the highest radiation doses of [124I]FIAU. The
effective dose was 0.16 to 0.20 mSv/MBq and doses to most organs ranged from 0.11 to 0.76 mGy/MBq.
PET image quality obtained from PJI patients was confounded by metal artifacts from the prostheses and pro-
nounced FIAU uptake in muscle. Consequently, a correlation with infection status and imaging results could
not be established.
Conclusions: [124I]FIAUwaswell-tolerated in healthy volunteers and subjects with suspected PJI, and had accept-
able dosimetry. However, the utility of [124I]FIAU for the clinical detection of PJIs is limited by poor image quality
and low speciﬁcity.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Amajor challenge in the treatment of prosthetic joint infection (PJI)
is the difﬁculty in distinguishing infection from sterile inﬂammation.
Often, there is uncertainty regardingwhether a prosthetic joint is infect-
ed or simply loose. Multiple factors currently considered by clinicians
attempting to make a diagnosis include medical history; physical
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examination ﬁndings; imaging ﬁndings on radiographs, computed
tomography (CT) and bone scintigraphy; pre-operative laboratory
evaluations (leukocyte count and differential, erythrocyte sedimenta-
tion rates [ESR], C-reactive protein [CRP], leukocyte esterase); and
the ﬁndings from pre-operative joint aspirates [1,2]. Sometimes, the
infection only can be ascertained intra-operatively through histology
and culture of specimens [3]. There is seldom any single pre-operative
test that is deﬁnitive [4,5], because current diagnostic tests have subop-
timal sensitivity and speciﬁcity [6]. Even after surgery, there are cases
where the level of diagnostic certainty is low, especially for infections
caused by indolent organisms or those with fastidious growth require-
ments [7,8]. A misdiagnosis has important consequences. If infection is
missed, prosthesis revision without appropriate débridement and anti-
biotic treatment, risks early failure and infection recrudescence.
Conversely, a false-positive diagnosis of prosthetic infection may result
in unnecessary invasive procedures, such as single or multi-staged
revisions [9,10].
Various radiopharmaceuticals have been investigated as potential
imaging agents to diagnose PJI, but all have important limitations
[11–14]. Bone scintigraphy measuring dynamic uptake of bone-
seeking tracers such as 99mTc-labeled diphosphonates, is used exten-
sively to assist the clinical management of numerous osseous patholo-
gies and is characterized by high sensitivity but low speciﬁcity for
diagnosis of PJI. At the present time, bone scintigraphy is used primarily
for screening purposes to exclude the possibility of any kind of loosen-
ing of the prosthesis. In vitro radiolabeled leukocyte scintigraphy has
been extensively studied for diagnosis of prosthesis infection but has
also yielded variable and often contradictory results. This has been at-
tributed to differences in acquisition, analysis, and interpretation proto-
cols between investigators and in patient characteristics impacting
sensitivity (presence of bioﬁlm around the infected prosthesis and in-
ﬂuence of antibiotics) or speciﬁcity (non-speciﬁc inﬂammation and in-
terference from ectopic bone marrow) [12]. Enhanced techniques (late
leukocyte scintigraphy, dual or serial time point leukocyte scintigraphy,
in vivo labeled leukocyte scintigraphy) and combination modalities
with bone scintigraphy, bone marrow scintigraphy, SPECT or SPECT/CT
have been developed, some with important improvement on the accu-
racy of infection diagnosis [13]. However, the complex labeling proce-
dures, the need to handle hazardous blood products, and cost remain
disadvantages for labeled leukocyte-based modalities [11,14]. Other
techniques such as [18F]ﬂuorodeoxyglucose ([18F]FDG) PET and scintig-
raphy with the radiolabeled antibiotic 99mTc-ciproﬂoxacin (Infecton)
have also been studied but neither is able to consistently differentiate
infection from aseptic inﬂammation. The published results on the role
of FDG PET in diagnosing PJI are controversial, reﬂecting the challenges
in image interpretation criteria, generation of artifacts, uptake by acti-
vated macrophages around inﬂamed prostheses, and the nonspeciﬁc
uptake by healing tissues post arthroplasty surgery [12,13]. The discrep-
ancy in the reported Infecton performance was probably due to bioﬁlm,
low bacteria count or resistance, and different labeling kit formulations
[12]. Therefore, radiopharmaceuticals that can reliably differentiate in-
fection from aseptic inﬂammation yet can be prepared routinely with
commercially available materials are warranted.
Preclinical data from a mouse model of infection demonstrated that
localized infections could be readily imagedwith 125I-FIAU, a nucleoside
analog that is a substrate for bacterial thymidine kinase (TK) and labels
bacteria at infection sites [15]. Subsequently, positron emission tomog-
raphy (PET) with [124I]FIAU was evaluated in a small human study of
eight patients with suspected musculoskeletal infections and one con-
trol subject [16]. The [124I]FIAU ﬁndings of infection versus non-
infection in all eight patients were consistent with those made based
on preoperative and intraoperative assessments, including cultures.
The preclinical and limited clinical data suggest that [124I]FIAU might
be a promising agent for diagnosing infections, including PJIs.
This prospective study assessed the dosimetry and safety of [124I]
FIAU in humans and the utility of [124I]FIAU PET/CT in diagnosing PJIs.
2. Materials and methods
This study was conducted in two parts. Part I, a phase 1 trial (http://
clinicaltrials.gov, NCT01337466) in two centers (Supplemental
Table S1), evaluated biodistribution and dosimetry of [124I]FIAU by
PET/CT in patients with hip or knee PJI and healthy subjects. Part II, a
phase 2 trial (http://clinicaltrials.gov, NCT01705496) in 8 centers (Sup-
plemental Table S1), evaluated the sensitivity and speciﬁcity of [124I]
FIAU PET/CT in patients presenting with pain in a prosthetic knee or
hip. All procedures performed in studies involving human participants
were in accordance with the ethical standards of the institutional and/
or national research committee and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.
2.1. Patients and Eligibility Criteria
Both trials were approved by the respective institutional review
boards at the participating sites. Prior to enrollment, all subjects gave
written informed consent.
Subjects with suspected PJI were required to have a prosthetic
joint implant in situ for N3 months prior to enrollment and were
required to have operative intervention planned within 30 days follow-
ing study enrollment.Womenwere either postmenopausal or surgically
sterile. Subjects with a history of an inherited mitochondrial disorder,
abnormal liver function, or hypersensitivity to iodine were excluded.
No subjects, except for one, received antibiotics in the 2 weeks preced-
ing imaging.
For thyroid protection, either saturated solution of potassium iodide
(SSKI) or Lugol's iodine was administered 1 h prior to dosing and con-
tinued for 7 days. Alternatively, potassium iodide tablets were adminis-
tered beginning 1 day prior to dosing and continued for 8 days.
A total of 12 subjects (6 healthy and 6 with suspected PJI) were en-
rolled in the phase 1 study and each received a single dose of
70.67–86.58 MBq (1.91–2.34 mCi) [124I]FIAU (except for 1 subject re-
ceiving 45.88 MBq because of a calibration error). The subjects
underwent whole-body PET/CT immediately after injection. Imaging
was repeated at 2, 4, and 6 h after dosing for all subjects; additional im-
aging at 24, 48, and 72 h after dosing was required for healthy subjects
and optional for subjects with suspected PJI. A low-dose CT protocol,
performed at 120 kVp and with mA as low as reasonably achievable,
was used for attenuation correction. The effective dose for each CT
scan at the two phase 1 sites was approximately 1.5–2 mSv. The PET
data from 10 subjects were used for estimation of dosimetry; images
for the other 2 subjects were excluded from the dosimetry analysis be-
cause of image acquisition and/or decay-correction errors.
For the phase 2 trial, 22 subjects with suspected PJI received a single
dose of 159.5–210.9 MBq (4.3–5.7 mCi) [124I]FIAU and 19 completed
the study. Two subjects discontinued early as “lost to follow-up”, and
one subject withdrew from the study. PET/CT of the area of interest
(hip or knee) was performed twice, 2–6 and 24–30 h, respectively,
after dosing.
Safetywas assessed by adverse event and vital signmonitoring, clin-
ical laboratory tests (serum chemistry including liver function tests,
complete blood count, and CRP), and physical examination for up to
30 days after dosing. All 34 subjects from both phase 1 and 2 were in-
cluded in the safety analysis.
2.2. Radiopharmaceutical
Each dose of [124I]FIAU [[124I]1-(2-deoxy-2-ﬂuoro-β-D-
arabinofuranosyl)-5-iodo-(2,4(1 H,3 H)-pyrimidinedione] was pro-
duced individually by 3D Imaging LLC. The speciﬁc activity was charac-
terized as 999–1295 GBq (27–35 Ci)/μmole (carrier-free), with N90%
radiochemical purity (remainder sodium iodide), and N99%
radionuclidic purity (remainder I-125). The administered mass of FIAU
was up to 0.12 μg.
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[124I]FIAU was supplied and shipped as a ready-to-inject sterile iso-
tonic saline solution with 5% ethyl alcohol as anti-radiolytic agent and
50 mM of sodium phosphate as buffering agent, pH 5.5–8.5 with a
shelf life of one half-life of 124I (4.2 days from synthesis time).
2.3. Image Analysis
Attenuation-corrected PET images were reconstructed with an iter-
ative reconstruction based on scanner manufacturer's recommenda-
tions. The 3–5 mm thick transaxial CT images were reconstructed at
contiguous intervals (or manufacturer's recommendation for overlap)
for fusion with the transaxial PET images. CT, attenuation-corrected
(AC) PET,metallic artifact algorithmattenuation-corrected PET (if avail-
able), and non-attenuation-corrected (NAC) PET images were generat-
ed and submitted to Icon Medical Imaging (IMI) for central archiving
and data analysis using a proprietary Medical Image Review and Analy-
sis (MIRA™) system.
PET image review was conducted using dedicated PET software
from MIM Software. The collected data were presented to a single
reader (JJC), blinded to clinical information, in sequential order, for a
qualitative assessment of both AC and NAC PET images. Target-to-
background ratios using the suspected infected joint as the target and
the contralateral muscle mass as the background, and standardized up-
take values (SUVmax, SUVmean and SUVpeak) were assessed. Repre-
sentative cases were then presented to 3 additional readers (BAS, AA,
SYC) for further evaluation.
2.4. Biodistribution and Dosimetry
Radioactivity concentrations were determined in various organs by
extraction of count data from PET images using MIPAV software [17].
Activity in each visualized organ and the total body were expressed as
fractions of injected activity, normalizing the activity in the whole
body at the earliest time point to 100% of the administered activity.
Values of the fraction of injected activity per organ were ﬁt using
SAAM II software [18]. Time-activity integrals [19] were entered into
OLINDA/EXM software [20], using the adult-male model. Tracer clear-
ance was assumed to only occur via urinary excretion; the whole-
body retention curvewas used to establish the kinetics of urinary excre-
tion. Calculations were made for assumed 3.5, 2.0 and 1.0 h bladder
voiding intervals. Theoretical calculations were also performed, assum-
ing complete renal obstruction in the subjects (all kidney and total body
activity assumed to be removed only by radioactive decay).
2.5. Surgical Sampling
At surgery, gross ﬁndings were documented, including the presence
of any purulent material or ﬂuid, and the surgeon's impression as to
whether the joint was infected. Results from microbiological and path-
ological studies performed as part of standard of care were recorded.
In cases where the periprosthetic membrane was removed, a minimum
of 6 samples fromdifferent areas and one control sample froma clinical-
ly uninfected area were obtained for histological and microbiological
testing. A central pathologist assessed all samples.
2.6. Independent Adjudication Board (IAB)
The IAB consisted of three clinicians specializing in infectious dis-
eases or orthopedics. For each case, the clinical, laboratory,microbiolog-
ical, and histologic data, along with radiologic assessments of
radiographs interpreted by a central radiologist, were independently
reviewed by each IAB member. Agreement in infection status between
at least two of the three IAB members constituted a closed case. Cases
where there was not 100% concordance between the three IAB mem-
bers were ﬂagged and reanalyzed to better understand the limitations
of the current diagnostic algorithm for patients with suspected PJI.
Our deﬁnition of PJI (supplemental information) is based on the
modiﬁed criteria proposed by the workgroup convened by the Muscu-
loskeletal Infection Society [1].
3. Results
3.1. Biodistribution and Dosimetry
The primary objective of the phase 1 study was to determine the
biodistribution and dosimetry of [124I]FIAU. Results showed that the
kidney, liver, spleen, and urinary bladder received the highest radiation
exposure with [124I]FIAU (Fig. 1). All data were ﬁt well with one or two
exponential functions.
Radiation exposures tomost organs ranged from 0.1 to 0.8 mGy/MBq,
with urinary bladder wall receiving 0.32, 0.49, and 0.76 mGy/MBq
with bladder voiding intervals of 1.0, 2.0, and 3.5 h after initial adminis-
tration of [124I]FIAU, respectively. The effective dose (ED) of [124I]FIAU
was approximately 0.16, 0.18, and 0.20 mSv/MBq, under the 3 assumed
voiding intervals (Table 1). Accordingly, for an administered activity of
185 MBq (5 mCi), the ED ranged from 29.5 to 36.0 mSv for the three
voiding intervals.
Based on model estimates, assuming complete renal obstruction
(Table 1; i.e., all elimination by radioactive decay), the kidney dose ap-
proximated 6.4 mGy/MBq and the ED approximated 0.29 mSv/MBq.
Imaging optimization and image quality was improved during the
conduct of the study. Photopenic areas (noted in areas of abdomen or
lower torso) were eliminated and/or reduced by changing the acquisi-
tion mode from 3D to 2D on the GE DST scanner (data not shown).
3.2. [124I]FIAU PET/CT Findings in Subjects With Suspected PJI
The utility of [124I]FIAU PET/CT for detection of PJI was assessed
by correlating scan ﬁndings determined by an independent image
reviewer and the infection status assessed by the IAB. The ﬁndings
were conﬁrmed by 3 additional readers reviewing representative
cases. The PET/CT interpreters relied on both AC and NAC scans for
their ﬁnal decision.
All [124I]FIAU PET/CT images revealed strong signals around the
metal prosthesis, indicating metal artifacts from CT-based attenuation
correction [21]. The NAC PET images often showed dramatically re-
duced counts around the prosthesis, conﬁrming that the increased PET
signal around the prosthesis on AC images was most likely attributable
tometal artifact, obscuring any speciﬁc butweakbacterial uptake signal.
Also noted in all PET images was pronounced diffuse muscle uptake.
None of the semiquantitative measures (target-to-background ratio,
SUVmax, SUVmean and SUVpeak) provided a unique signature for in-
fection that was not confounded by artifacts or muscle uptake of the
tracer around the prostheses.
Among the 19 subjects with suspected PJI who completed the phase
2 study, 4 were treated as infected by the operating surgeons, although
the IAB considered only 3 as infected based on the pre-deﬁned PJI
criteria. One of these three subjects (Table S2) had bilateral knee re-
placements, and left-sided PJI was suspected. Two of 6 samples taken
from suspected areas of infection during surgery were culture positive
for coagulase-negative Staphylococcus, and thus categorized as infected
by the IAB. On the 27-h PET/CT images (Fig. 2), while metal artifacts, as
indicated by bilateral posterior focal uptake (Fig. 2A), and muscle up-
take (Fig. 2B) were both prominent, there was an area of greater signal
in the left anterior knee by comparison with the right knee, suggesting
potential bacterial uptake (Fig. 2C). Another subject (Table S3) studied
at the same site and imagedwith the same scanner, had a right knee re-
placement in 2009, but had experienced constant pain ever since. None
of the pre-operative tests suggested infection. No evidence of acute in-
ﬂammation or loosening was observed during surgery. Intra-operative
frozen section revealed synovial tissue with chronic inﬂammation,
granulation tissue, and reactive changes, but neither histopathology
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nor cultures of 6 surgical samples showed evidence of infection. There-
fore, the joint was considered uninfected by both the surgeon and the
IAB. Discordantly, intense [124I]FIAU uptake was detected in the pros-
thetic knee and muscles (Fig. 3).
The independent PET/CT image reviewers had difﬁculty differentiat-
ing uninfected from infected cases based only on regional [124I]FIAU up-
take, primarily because of the metal artifact and high muscle
background. Consequently, an independent image review charter
could not be deﬁned to guide the assessment of the PET and PET/CT
images. No correlation could be established between infection status
based on all clinical information and the blinded assessment of the
PET/CT images.
3.3. Safety
[124I]FIAUwaswell tolerated in healthy volunteers and subjectswith
suspected PJI. None of 9 adverse events (AEs) reported in the phase 1
trial was considered to be related to the study drug, none was severe,
and none led to study discontinuation. Overall, 15 subjects (68.2%)
from the phase 2 trial experienced AEs. However, only 2 patients, who
each noted paresthesias and injection site pain, had study drug-
related AEs that were mild and occurred only on the day of dosing.
Only 3 AEs were severe, but none led to study discontinuation. Three
subjects experienced SAEs (2 in phase 1: gastric ulcer with hemorrhage,
and pain; and 1 in the phase 2: severe drug hypersensitivity to a con-
comitant medicine), but none of the SAEs was considered as study
drug-related. No clinically meaningful trends were noted in vital signs,
physical examination ﬁndings, electrocardiograms or laboratory test re-
sults, including liver function tests, lactate, serum chemistry, and com-
plete blood count. There were no clinically detectable pharmacologic
effects attributable to administration of [124I]FIAU.
4. Discussion
Fialuridine (FIAU) was developed as a therapeutic agent for chronic
hepatitis B infection, but the clinical programwas terminated because of
serious toxicity that resulted in death or the need for liver transplant
among patients in a phase 2b study [22]. These serious toxicities oc-
curred at cumulative total doses in excess of 500mgwhen FIAUwas ad-
ministered over time with repeated dosing [23]. Importantly, the single
diagnostic imaging dose of [124I]FIAU used in the present study was
b0.12 μg, nearly 30,000-fold lower than the lowest daily dose
(~3.5 mg) administered chronically in the therapeutic studies. We
have found that 74–185 MBq (2–5 mCi) [124I]FIAU was well-tolerated
in all subjects tested. No clinically meaningful trends were noted in
the laboratory test results, including liver function tests. None of the
SAEs were considered to be [124I]FIAU drug related.
Fig. 1. Normal biodistribution of [124I]FIAU.Maximal-intensity-projection (MIP) PET image (a) and fused coronal PET/CT image (b) at 4 h after injection in a healthy volunteer. Prominent
activity is seen in the kidneys, liver, spleen and urinary bladder.
Table 1









mGy/MBq mGy/MBq mGy/MBq mGy/MBq
Adrenals 1.68E-01 1.68E-01 1.68E-01 4.81E-01
Brain 1.24E-01 1.24E-01 1.24E-01 1.97E-01
Breasts 1.16E-01 1.16E-01 1.16E-01 1.93E-01
Gallbladder wall 1.73E-01 1.72E-01 1.72E-01 3.76E-01
LLI wall 1.85E-01 1.77E-01 1.72E-01 2.84E-01
Small intestine 1.78E-01 1.74E-01 1.73E-01 3.34E-01
Stomach wall 1.62E-01 1.62E-01 1.62E-01 3.27E-01
ULI wall 1.73E-01 1.70E-01 1.69E-01 3.24E-01
Heart wall 1.89E-01 1.89E-01 1.89E-01 2.73E-01
Kidneys 3.08E-01 3.08E-01 3.07E-01 6.42E + 00
Liver 1.49E-01 1.49E-01 1.49E-01 2.74E-01
Lungs 1.41E-01 1.41E-01 1.41E-01 2.42E-01
Muscle 1.43E-01 1.41E-01 1.39E-01 2.51E-01
Ovaries 1.89E-01 1.81E-01 1.76E-01 2.97E-01
Pancreas 1.77E-01 1.76E-01 1.76E-01 4.19E-01
Red marrow 1.35E-01 1.34E-01 1.33E-01 2.66E-01
Osteogenic cells 2.04E-01 2.03E-01 2.03E-01 3.47E-01
Skin 1.09E-01 1.09E-01 1.08E-01 1.87E-01
Spleen 2.23E-01 2.23E-01 2.23E-01 4.57E-01
Testes 1.50E-01 1.45E-01 1.41E-01 2.21E-01
Thymus 1.46E-01 1.46E-01 1.46E-01 2.38E-01
Thyroid 1.45E-01 1.45E-01 1.45E-01 2.33E-01
Urinary bladder wall 7.57E-01 4.92E-01 3.20E-01 2.70E-01
Uterus 2.14E-01 1.95E-01 1.82E-01 2.99E-01
Total body 1.45E-01 1.43E-01 1.42E-01 2.77E-01
Effective dose (mSv/MBq) 1.95E-01 1.77E-01 1.59E-01 2.88E-01
276 X.M. Zhang et al. / Nuclear Medicine and Biology 43 (2016) 273–279
The biodistribution of [124I]FIAU is generally similar to that of
radiolabeled leukocytes and [18F]FDG, two other radiopharmaceuticals
available for clinical diagnosis of PJI (albeit with mixed results), except
for additional bone marrow uptake seen with radiolabeled leukocytes
[24], and additional high brain uptake and variable myocardial and
bowel uptakewith [18F]FDG [25]. The ED of [124I]FIAU is higher for a sin-
gle scan (74–185MBq at 0.16 to 0.20 mSv/MBq), compared to thatwith
18F-FDG (370–740 MBq at 0.019 mSv/MBq) and radiolabeled leuko-
cytes (111In-leukocytes: 10–18.5 MBq at 0.59 mSv/MBq; 99mTc-
HMPAO leukocytes: 185–370 MBq at 0.017 mSv/MBq).
[124I]FIAU PET/CTwas evaluated for its potential utility in diagnosing
PJIs. Data from a rodent model showed that bacteria-infected muscle
had a much greater imaging signal than noninfected muscle [15]. In ad-
dition, a muscle infection with a tk-deleted E. colimutant resulted in no
imaging signal. These observations suggested that FIAU was effectively
phosphorylated by bacterial TKs and that bacterial FIAU uptake could
be readily detected by radionuclide imaging. In a small human study,
Diaz et al. performed [124I]FIAU PET/CT in 8 subjects with suspected
musculoskeletal infections [16]. Three out of the 8 patients had
suspected hip or knee PJI; [124I]FIAU PET/CT was true-positive for
Fig. 2. True-positive scan; left knee prosthetic joint infection. The transverse, sagittal and coronal [124I]FIAU PET images (a–c), and fused PET/CT images (d–f) at 27 h after injection in a
patient with bilateral knee replacements show pronounced metal artifacts (arrow head, a) and muscle uptake (arrow head, b). The arrow in (c) points to the increased focal uptake in
the left knee compared to the right knee.
Fig. 3. False-positive scan. The transverse, sagittal and coronal [124I]FIAU PET images (a–c), and fused PET/CT images (d–f) at 24 h after injection in a subject with suspected right knee PJI
show pronounced metal artifacts (arrow head, a) and muscle uptake (arrow head, b). The arrow in (c) points to increased focal uptake in the right knee compared to the left knee.
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infection in two, who either had positive joint aspirate culture or multi-
ple areas of infection noted during surgery, suggesting a high bacterial
load. [124I]FIAU PET/CT was true negative in the third patient.
In our clinical trials, we enrolled subjects who did not have overt
signs or symptoms of infection. These patients required operative inter-
vention to correct pain in the prosthetic joint, irrespective of pre-
operative test results. Because of the lack of a well-validated truth stan-
dard for diagnosing PJI, such patients pose a marked diagnostic
challenge. Clinicians are often forced to explore the prosthetic joint de-
spite no clear pre-operative diagnosis and tomodify their surgery based
on intraoperative ﬁndings. Many patients will have chronic and/or in-
dolent infections with low bacterial load or subtle infections located in
bioﬁlms [26]. If the bacteria are in a quiescent state, there will be little
uptake of a metabolic agent like FIAU. Further adding to the diagnostic
challenges is the difﬁculty in detecting fastidious organisms with stan-
dard microbiological assays [7,27].
To diagnose PJI conﬁdently in these difﬁcult cases, an effective imag-
ing technologymust be able to detect bacterial infectionswith high sen-
sitivity and speciﬁcity.Whereas, 18F-FDG PET/CT imaging has been used
in assessing periprosthetic infections, it cannot discriminate aseptic
from septic inﬂammation. In our phase 1 and phase 2 PJI studies, inﬂam-
mationwasnoted for a number of subjects in the operative reports or on
histologic examination of tissue samples obtained at surgery. This ob-
servation raised the question whether the FIAU signal detected around
the prosthesis of interest at least partially came from the uptake by in-
ﬂammatory cells. We performed [124I]FIAU PET/CT imaging in a murine
collagen-induced arthritis (CIA) model to assess whether FIAU was in-
corporated by host inﬂammatory cells (supplemental information).
Themouse imaging data suggest that the FIAUuptake initially increased
at the inﬂamed sites, likely due to increased blood volume that is com-
monly associated with inﬂammation, and the uptake decreased as the
agent cleared from the circulation. However, even with the 4.2-day
half-life of 124I, no increased [124I]FIAU signal was observed in the in-
ﬂamed areas of diseased animals compared to naïve animals at 24 and
48 h post-injection (Figure S1). Therefore, there was no evidence
that FIAU was speciﬁcally taken up by the inﬂammatory cells at the
joint of interest.
Nevertheless, our experience with [124I]FIAU PET/CT imaging argues
against its potential as a robust imaging tool for PJI diagnosis. The spec-
iﬁcity for bacterial infection was suboptimal. Metal artifacts in CT im-
ages resulted in pronounced PET signal localized to the prosthetic
joint attributable to attenuation correction artifact,making theunequiv-
ocal detection of bacteria-speciﬁc uptake very challenging, particularly
in cases where only a unilateral prosthesis was present. The observed
high diffuse muscle uptake of FIAU was bilateral, not limited to speciﬁc
muscle groups, and involvedmuscles not just near the joint. There were
no clearly discernable differences in muscle uptake between subjects
with infected PJI and those without. The muscle uptake of [124I]FIAU
has also been reported by Diaz et al. in their small human study [16].
Similar ﬁndings were described in [18F]FIAU studies of experimental
dogs [28]. Not surprisingly, myopathy was an adverse effect associated
with chronic FIAU treatment of human hepatitis B infection [23].Wehy-
pothesize that the muscle uptake may be the result of human rather
than bacterial TK activity, since FIAU is a known substrate for human
TK's (cytoplasmic TK1 and mitochondrial TK2). FIAU was reported to
be as good a substrate as thymidine for human TK2 [29], although the
catalytic efﬁciency of human TK1 for FIAU was ~60 fold lower [30].
TK2 also shares more sequence similarity to bacterial TKs than TK1
does. In addition, TK1 is only expressed in S-phase cells, while TK2 is
constitutively expressed in all tissues. Indeed, while TK1 is not
expressed in muscle, a resting cell type, it is one of the tissues where
TK2 mRNAs are predominantly expressed [31]. It is tempting to specu-
late that this FIAU muscle uptake reﬂects mitochondrial TK2 activity.
Unfortunately the muscle signal markedly compromised our ability to
detect bacteria-speciﬁc uptake, especially in the patients in the current
study where the bacterial burden was assumed to be low. One of the
major hurdles with detection of small numbers of bacteria by PET is
the limited spatial resolution,whichmakes it extremely difﬁcult to visu-
alize lowuptake of a targeted PET agent compared to thehigh surround-
ing background. It is also worth noting that an 124I labeled tracer, with
only 25.6% decay by positron emission, generally displays inferior imag-
ing characteristics than an 18F-labeled tracer, with 97% positron decay
and that is typically given in much higher quantity. This has likely con-
tributed to the low sensitivity of [124I]FIAU for bacteria imaging.
The reasons for using 124I-labeled instead of 18F-labeled FIAU in our
studies were multiple. First, chronic PJIs typically involve slow-growing
bacteria. We and the study performed under RDRC approval at Johns
Hopkins University (Martin Pomper and Steve Cho, personal communi-
cations) have found that delayed imaging until 24 h post FIAU dosing
was required to increase speciﬁc bacterial uptake and optimize the
signal-to-noise ratio in cases of infection with a low bacteria load.
With an 18F half-life of 109.8 min, delayed imaging at 24 h is not possi-
ble with [18F]FIAU. Second, the long half-life of 124I allows for once a
week production in a central facility and wide distribution throughout
the country to promote clinical application. Last, the synthesis of [18F]
FIAU is more complex and achieves much lower yield than that of
[124I]FIAU. We considered using [18F]FIAU early on for our study, but
the manufacturer could not obtain high enough yield to make this ap-
proach scalable to a level that would have been sufﬁcient for our
multi-site trials, let alone future commercial use. PET images likely
would have had better resolution with [18F]FIAU, but the CT streak arti-
facts and possibly muscle uptake would have remained problematic.
Overall, compromises had to be made on the choice of tracer based on
radionuclide properties, taking into account the target patient popula-
tion, the long term goal of commercialization and real life logistical con-
straints. We could have increased the quality of the PET images by
requiring scanners with metal-artifact reduction reconstruction algo-
rithms, or scanners that can perform dual-energy CT for artifact reduc-
tion. However, since nearly all PET-CT scanners in US at the time did
not have these desirable features, this would have been a limitation to
wide patient access.
It is important to point out that [124I]FIAU could be a potential
tracer for infections caused by certain non-bacterial organisms, includ-
ing Herpes-simplex virus, and other viruses with homology to HSV-1
thymidine kinase protein (HSV-1 tk), such as Epstein–Barr virus
(EBV). In a clinical setting that is not confounded by metal artifacts or
extremely low infection burden, FIAU may still have utility for imaging
infection [32].
5. Conclusion
[124I]FIAU was well-tolerated in healthy volunteers and subjects
with suspected PJI, and had acceptable dosimetry. However, the utility
of [124I]FIAU in the detection of PJI in the clinic is limited by low image
quality as a result of metal artifact and high background from non-
speciﬁc muscle uptake.
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